Immunomic Therapeutics, Inc. will present preclinical data on its investigational nucleic acid platform, UNITE (Universal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mice.
UNITE fuses a tumor-associated antigen, here a mutated form of the large T antigen (LT) of Merkel cell polyomavirus (MCPyV), with lysosomal-associated membrane protein 1 (LAMP1).
The majority of Merkel cell carcinomas (MCC) are associated with Merkel cell polyomavirus (MCPyV) infection, making LT an attractive target for therapeutic cancer vaccines.
The results of this study confirmed the specific antigen immune activation against polyomavirus by ITI-3000 test on mice. It contains major immune cell activity such as CD4+ and CD8+ T cells and cytokine secretion.
“ITI-3000 is an innovative and novel targeted approach to a MCPyV vaccine,” says Teri Heiland, Ph. D., Immunomic’s Chief Scientific Officer. “We are highly encouraged by this data and look forward to continuing to advance ITI-3000 toward the clinic.”
The data will be presented at AACR Virtual Annual Meeting II, June 22-24, 2020.